A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

BACKGROUND: Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patients. METHO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Mei, Heng, Liu, Xiaofan, Li, Yan, Zhou, Hu, Feng, Ying, Gao, Guangxun, Cheng, Peng, Huang, Ruibin, Yang, Linhua, Hu, Jianda, Hou, Ming, Yao, Yazhou, Liu, Li, Wang, Yi, Wu, Depei, Zhang, Liansheng, Zheng, Changcheng, Shen, Xuliang, Hu, Qi, Liu, Jing, Jin, Jie, Luo, Jianmin, Zeng, Yun, Gao, Sujun, Zhang, Xiaohui, Zhou, Xin, Shi, Qingzhi, Xia, Ruixiang, Xie, Xiaobao, Jiang, Zhongxing, Gao, Li, Bai, Yuansong, Xiong, Junye, Li, Runzi, Zou, Jianjun, Niu, Ting, Yang, Renchi, Hu, Yu
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7905908/
https://ncbi.nlm.nih.gov/pubmed/33632264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01047-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados